CRL vs. MEDP, INCY, ICLR, IQV, RDY, SNN, UHS, DVA, SRPT, and UTHR
Should you be buying Charles River Laboratories International stock or one of its competitors? The main competitors of Charles River Laboratories International include Medpace (MEDP), Incyte (INCY), ICON Public (ICLR), IQVIA (IQV), Dr. Reddy's Laboratories (RDY), Smith & Nephew (SNN), Universal Health Services (UHS), DaVita (DVA), Sarepta Therapeutics (SRPT), and United Therapeutics (UTHR). These companies are all part of the "medical" sector.
Medpace (NASDAQ:MEDP) and Charles River Laboratories International (NYSE:CRL) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, community ranking, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.
78.0% of Medpace shares are held by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are held by institutional investors. 20.3% of Medpace shares are held by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Medpace had 9 more articles in the media than Charles River Laboratories International. MarketBeat recorded 19 mentions for Medpace and 10 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 1.08 beat Medpace's score of 0.88 indicating that Medpace is being referred to more favorably in the media.
Charles River Laboratories International has higher revenue and earnings than Medpace. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.
Medpace has a net margin of 15.92% compared to Medpace's net margin of 10.81%. Charles River Laboratories International's return on equity of 59.74% beat Medpace's return on equity.
Medpace currently has a consensus price target of $441.67, indicating a potential upside of 13.04%. Charles River Laboratories International has a consensus price target of $255.27, indicating a potential upside of 19.00%. Given Medpace's higher possible upside, analysts clearly believe Charles River Laboratories International is more favorable than Medpace.
Medpace has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Charles River Laboratories International has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500.
Charles River Laboratories International received 144 more outperform votes than Medpace when rated by MarketBeat users. However, 64.07% of users gave Medpace an outperform vote while only 61.51% of users gave Charles River Laboratories International an outperform vote.
Summary
Medpace beats Charles River Laboratories International on 11 of the 18 factors compared between the two stocks.
Get Charles River Laboratories International News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Charles River Laboratories International Competitors List
Related Companies and Tools
